TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2288051

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg orally, twice a day for 4 days
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally, twice a day for 4 days
Number of subjects: 61
Study: 7293935

Group type: EXPERIMENTAL
Intervention: Amino acid preparation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31971899

Group type: EXPERIMENTAL
Intervention: VASCADE MVP Venous Vascular Closure System (VVCS)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 204
Study: 30929415

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29967411

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (inactive treatment)
Number of subjects: 40
Study: 26573431

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24928802

Group type: EXPERIMENTAL
Intervention: CO2-releasing suppository
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 23210068

Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Midazolam-dexamethasone (0.075 mg/kg + 0.05 mg/kg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Midazolam-dexamethasone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 66
Study: 19279077

Group type: EXPERIMENTAL
Intervention: High dietary protein (20% energy)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low dietary protein (10% energy)
Number of subjects: 27
Study: 17618098

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Allium sativum
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15126745

Group type: EXPERIMENTAL
Intervention: PET placement
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PET placement and adenoidectomy
Number of subjects: 63
Study: 11590899

Group type: EXPERIMENTAL
Intervention: HLA-DR2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DQB1*0501
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DQB1*0601
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DR2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DR2, DQB1*0501, DQB1*0601
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DQB1*0503
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DQB1*0201 and DPB1*0901
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DQA1*0601 and DQB1*0503 and *0301
Number of subjects: 56
Study: 9713301

Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 150
Study: 7889885

Group type: EXPERIMENTAL
Intervention: Boron supplementation (2.5 mg for 7 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (Boron and Placebo)
Number of subjects: 19
Study: 3300457

Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 240 mg twice a day)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 to 180 mg twice a day)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Propranolol with Hydrochlorothiazide (for patients not achieving treatment goal)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 196
Study: 29529656

Group type: EXPERIMENTAL
Intervention: XLPE liners
Number of subjects: 220

Group type: COMPARATOR
Intervention: CPE liners
Number of subjects: 220
Study: 28974165

Group type: EXPERIMENTAL
Intervention: Attention-training intervention (Pay Attention!)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Play control group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Test-only control group
Number of subjects: 15
Study: 26537941

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Antiretrovirals (zidovudine/lamivudine and nelfinavir or lopinavir/ritonavir)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) with antiretrovirals
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 537
Study: 23535340

Group type: EXPERIMENTAL
Intervention: MISC caregiver training program
Number of subjects: 119

Group type: COMPARATOR
Intervention: Health and nutrition curriculum (Control)
Number of subjects: 119
Study: 22017782

Group type: EXPERIMENTAL
Intervention: Naproxen 275 mg every 12 hours for 120 hours
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo 275 mg every 12 hours for 120 hours
Number of subjects: 161
Study: 17634178

Group type: EXPERIMENTAL
Intervention: Lingual 24% sucrose (0.5-2 ml varying with body weight) administered 2 min before nasogastric tube insertion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water placebo (0.5-2 ml varying with body weight) administered 2 min before nasogastric tube insertion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lingual 24% sucrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 20
Study: 12871445

Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU anti-factor Xa, first dose 6 h after surgery)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg, first dose 12 h before surgery)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 381

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 381
Study: 10594526

Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Melatonin 5.0 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7849309

Group type: EXPERIMENTAL
Intervention: Leukemic cells causing histopathologically detectable leukemia in SCID mice
Number of subjects: 42

Group type: COMPARATOR
Intervention: Leukemic cells not causing histopathologically detectable leukemia in SCID mice
Number of subjects: 42
Study: 2352250

Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ortho‐Novum 7/7/7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ortho‐Novum 1/35
Number of subjects: 0
Study: 392853

Group type: EXPERIMENTAL
Intervention: L-lysine monohydrochloride, 1,000 mg daily for five days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 31597523

Group type: EXPERIMENTAL
Intervention: Ectopic overexpression of miR-149 by transfecting miR-149 mimics
Number of subjects: 0

Group type: COMPARATOR
Intervention: CircRNA-HIPK3
Number of subjects: 0
Study: 30496612

Group type: EXPERIMENTAL
Intervention: Aging for 28 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Aging time
Number of subjects: 5
Study: 28877404

Group type: EXPERIMENTAL
Intervention: PWB training (six-session intervention)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 32
Study: 25822924

Group type: EXPERIMENTAL
Intervention: Nebulized ketamine (2 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nebulized dexmedetomidine (2 μg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined nebulized dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg)
Number of subjects: 60
Study: 23818535

Group type: EXPERIMENTAL
Intervention: Intervention (information leaflet, two telephone calls, letters over 12 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual treatment alone (Control)
Number of subjects: 66
Study: 21114602

Group type: EXPERIMENTAL
Intervention: 12 Oral-lyn puffs (1 puff = 1 s.c. rapid insulin UI), split into two doses before and after OGTT
Number of subjects: 31

Group type: COMPARATOR
Intervention: 6 Oral-lyn puffs (used in group C)
Number of subjects: 31
Study: 19182178

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social activity therapy (SAT)
Number of subjects: 0
Study: 17483968

Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin gel for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotretinoin after placebo for 4 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical analysis
Number of subjects: 20
Study: 15464315

Group type: EXPERIMENTAL
Intervention: QuaDDS stents (13- and 17-mm)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control stents (uncoated)
Number of subjects: 266
Study: 11448318

Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy for choroidal melanoma
Number of subjects: 8712

Group type: EXPERIMENTAL
Intervention: Eligible patients who enrolled
Number of subjects: 8712

Group type: COMPARATOR
Intervention: Eligible patients not enrolled
Number of subjects: 8712

Group type: COMPARATOR
Intervention: Ineligible patients
Number of subjects: 8712

Group type: EXPERIMENTAL
Intervention: Enrolled patients
Number of subjects: 8712
Study: 9579836

Group type: EXPERIMENTAL
Intervention: PBPC+G‐CSF (n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: PBPC alone (n = 12)
Number of subjects: 23
Study: 8043974

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kgBW daily for 1 week, then tapered by 0.1 mg/kg BW/week for 1 month) and chlorambucil (0.12 mg/kgBW daily) administered during months 1-6.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone and chlorambucil therapy
Number of subjects: 17
Study: 3052785

Group type: COMPARATOR
Intervention: Metoclopramide (MCP) alone (total dose, 6 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) plus Dexamethasone (DMS) (total dose, 60 mg)
Number of subjects: 50
Study: 30500309

Group type: EXPERIMENTAL
Intervention: Five weekly cellphone-delivered sessions of stigma and alcohol-enhanced behavioural self-regulation counselling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Contact matched control condition
Number of subjects: 50
Study: 28182243

Group type: EXPERIMENTAL
Intervention: Cut‐down‐to‐quit (CDTQ)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Quit immediately (QI)
Number of subjects: 1077
Study: 25522265

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (200 μmol SFN daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myrosinase-treated broccoli sprout extract (BSE) (200 μmol SFN daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice daily dosing (two 100-μmol doses taken 12 h apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose (200 μmol SFN)
Number of subjects: 0
Study: 23575739

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heart failure patients
Number of subjects: 11
Study: 20929915

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose 1000 mg over 15 min (with up to two additional doses of 500 mg at 2-week intervals)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose 1000 mg over 15 min
Number of subjects: 255

Group type: COMPARATOR
Intervention: Oral ferrous sulphate 325 mg thrice daily for a total of 195 mg elemental iron daily for 56 days
Number of subjects: 255

Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 255
Study: 19829198

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 232
Study: 18236203

Group type: EXPERIMENTAL
Intervention: 8-week treatment group (n = 10)
Number of subjects: 34

Group type: COMPARATOR
Intervention: no-intervention group (n = 15)
Number of subjects: 34
Study: 15015440

Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (ICWM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 60
Study: 11685409

Group type: EXPERIMENTAL
Intervention: Visual-only series
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Visual-vestibular series (0.8 Hz)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Visual-vestibular series (0.1 Hz)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Visual-vestibular- neck series
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Targets presented at SSA
Number of subjects: 6
Study: 9532649

Group type: EXPERIMENTAL
Intervention: Ascolong (12.5 mg) administered once or regularly for 2 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ascolong (12.5 mg)
Number of subjects: 62
Study: 8057111

Group type: EXPERIMENTAL
Intervention: Low dose levodopa-carbidopa (<= 600/150 mg/day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Low dose bromocriptine (<= 30 mg/day)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa (added to bromocriptine)
Number of subjects: 149
Study: 2970159

Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate in alcoholic solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel
Number of subjects: 60
Study: 29126209

Group type: EXPERIMENTAL
Intervention: SmokeBeat app for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study: 28284888

Group type: EXPERIMENTAL
Intervention: Educational intervention and sleep hygiene
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 125
Study: 26699542

Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM)
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Non-Chinese Herbal Medicine (non-CHM)
Number of subjects: 1960
Study: 23152361

Group type: EXPERIMENTAL
Intervention: Irsogladine maleate (IM) 4 mg/day for 14 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19189989

Group type: EXPERIMENTAL
Intervention: Acupuncture and auricular acupressure (n = 21)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT) - Tibolone (n = 25)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 18165043

Group type: EXPERIMENTAL
Intervention: Midvastus approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 20
Study: 16676251

Group type: EXPERIMENTAL
Intervention: Revascularization and replantation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 12
Study: 15120550

Group type: EXPERIMENTAL
Intervention: Reicher-Wheeler task with eye-tracking for word recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reicher-Wheeler task with eye-tracking for non-word recognition
Number of subjects: 0
Study: 10904853

Group type: EXPERIMENTAL
Intervention: Treatment according to the etiology of the disease (specific treatment not detailed in the abstract)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as part of the American Myocarditis Treatment Trial)
Number of subjects: 182
Study: 9488974

Group type: EXPERIMENTAL
Intervention: Zidovudine for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zidovudine or didanosine before and after treatment
Number of subjects: 40
Study: 7870965

Group type: EXPERIMENTAL
Intervention: Cocaine administered alone (4-96 mg/70 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol administered alone (0-1.0 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine and alcohol combined
Number of subjects: 0
Study: 2877683

Group type: EXPERIMENTAL
Intervention: Nitrous oxide and enflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Narcotic-barbiturate technique
Number of subjects: 20
Study: 28639841

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), a structured eight-week mindfulness-based educational and training programme
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study: 25887111

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg before bedtime for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo before bedtime for 4 weeks
Number of subjects: 16
Study: 24887018

Group type: EXPERIMENTAL
Intervention: 1 night of unrestricted sleep (n=13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1 night of total sleep deprivation (24 hours of wakefulness) (n=13)
Number of subjects: 26
Study: 22925428

Group type: EXPERIMENTAL
Intervention: Reimbursement for smoking cessation treatment
Number of subjects: 187

Group type: COMPARATOR
Intervention: Traditional productivity cost estimates
Number of subjects: 187

Group type: COMPARATOR
Intervention: Adjusted productivity cost estimates
Number of subjects: 187

Group type: COMPARATOR
Intervention: Combined impacts of compensation and multiplier effects
Number of subjects: 187
Study: 21211458

Group type: EXPERIMENTAL
Intervention: Somatostatin group (n = 23)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: SSC Group (n = 30)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 53
Study: 18533353

Group type: EXPERIMENTAL
Intervention: Activia yogurt (2 units/day)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Lacteous dessert without probiotics (control)
Number of subjects: 378
Study: 15948996

Group type: EXPERIMENTAL
Intervention: Oral pimecrolimus 30 mg twice daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Oral pimecrolimus 20 mg twice daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Oral pimecrolimus 10 mg twice daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 14632333

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: nCPAP and Conventional ventilation
Number of subjects: 42
Study: 10888946

Group type: EXPERIMENTAL
Intervention: Active treatment (frequently repeated active submaximal movements combined with mechanical diagnosis and therapy)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Active treatment (early administration within 96 hours)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard treatment (initial rest, recommended use of a soft collar, gradual self-mobilization)
Number of subjects: 97
Study: 8645068

Group type: EXPERIMENTAL
Intervention: Aortography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic chest computed tomography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation with follow-up chest radiography
Number of subjects: 0
Study: 1416808

Group type: COMPARATOR
Intervention: Valproate (VPA), 15 mg/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM), 3,600 mg/day
Number of subjects: 44
Study: 2992898

Group type: EXPERIMENTAL
Intervention: Active marijuana (2.9% delta 9THC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (0.0% delta 9THC)
Number of subjects: 13
Study: 29496255

Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg twice daily) plus Erlotinib (150 mg daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single-agent chemotherapy (investigator's choice of pemetrexed, docetaxel, or gemcitabine)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single-agent chemotherapy (C)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tivantinib plus Erlotinib (ET)
Number of subjects: 96
Study: 26825266

Group type: EXPERIMENTAL
Intervention: Family-to-Family intervention (FTF)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Waitlist condition (Control)
Number of subjects: 318
Study: 24655901

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine‐gluconate ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% povidone‐iodine
Number of subjects: 0
Study: 22997204

Group type: EXPERIMENTAL
Intervention: BNP-driven fluid management strategy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Physician-driven strategy
Number of subjects: 304
Study: 20492438

Group type: EXPERIMENTAL
Intervention: 30-min tongue-task training regime
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lidocaine tongue-task training regime
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Capsaicin tongue-task training regime
Number of subjects: 72

Group type: COMPARATOR
Intervention: 15-min tongue-task training regime
Number of subjects: 72
Study: 18632218

Group type: EXPERIMENTAL
Intervention: Oral visual inspection intervention
Number of subjects: 96517

Group type: EXPERIMENTAL
Intervention: Screened individuals
Number of subjects: 96517

Group type: EXPERIMENTAL
Intervention: Age factor in screening
Number of subjects: 96517

Group type: EXPERIMENTAL
Intervention: Household size
Number of subjects: 96517

Group type: EXPERIMENTAL
Intervention: Compliance with referral
Number of subjects: 96517
Study: 15978535

Group type: EXPERIMENTAL
Intervention: salbutamol (600 microg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 12192164

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (various types)
Number of subjects: 25
Study: 9524967

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2) during sedation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-supplemental oxygen (non-O2) during sedation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2) during postoperative period
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-supplemental oxygen (non-O2) during postoperative period
Number of subjects: 14
Study: 7924477

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG), 40 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: No intervention (test A without premidication)
Number of subjects: 17
Study: 2451414

Group type: EXPERIMENTAL
Intervention: encainide
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: flecainide
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: moricizine
Number of subjects: 687

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 687